Who should not take ARA-290 (Cibinetide)?
Documented caution flags for ARA-290 (Cibinetide) include pregnancy / nursing and active malignancy, limited data. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for ARA-290 (Cibinetide) is limited.
Documented caution flags for ARA-290 (Cibinetide)
- Pregnancy / nursing
- Active malignancy, limited data
Reported side effects to weigh
- Generally well tolerated
- Rare: mild headache
- Injection-site reaction
References
- ARA-290 (cibinetide) in sarcoidosis-associated small fiber neuropathy — Heij L et al., Mol Med, 2012
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density — Dahan A, Dunne A, Swartjes M, et al. (Brines M, senior author) — Molecular Medicine, 2013
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Brines M, Dunne AN, van Velzen M, et al. — Molecular Medicine, 2015
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ARA-290 (Cibinetide)
Full ARA-290 (Cibinetide) breakdownARA-290 (Cibinetide) what it's used forARA-290 (Cibinetide) side effectsARA-290 (Cibinetide) how to take itARA-290 (Cibinetide) mistakes to avoidARA-290 (Cibinetide) half-lifeARA-290 (Cibinetide) how long to workARA-290 (Cibinetide) legal statusARA-290 (Cibinetide) how it worksAsk the AI Coach
Last updated 2026-06-15.